Market Overview

Global Biopsy Devices Market size was valued at around 2.22 billion in 2023 and is expected to reach a value of USD 4.05 billion by 2032, at a CAGR of 5.9% over the forecast period (2024–2032).

The major factors propelling industry growth include the rise in cancer prevalence, the rise in interest for minimally invasive procedures, untapped opportunities in developing countries especially in Asia Pacific, and an improvement in the healthcare infrastructure.

The Union for International Cancer Control estimates that more than 35 million new cases of cancer will occur in 2050, which is 77% more than the 20 million predicted cases of cancer in 2022.  An increase in the incidence rate of cancer is estimated to drive market growth and amplify demand for biopsy equipment.

Moreover, the increased demand for these minimally invasive procedures has come with benefits; patients heal fast and experience trauma as a consequence of these surgical operations. It has made the market more innovative because of increasing demand for this minimally invasive procedure. Recently, for example, physicians from NewYork-Presbyterian/Columbia unveiled new technique in July 2022 that offers an easier, less invasive, safer, and much quicker way of performing lung biopsies.

The rising incidence of cancer is driving the need for efficient detection techniques. This has made more government agencies spend more on cancer research. For instance, the National Cancer Institute had a total of USD 6.8 billion in funds available in 2022, a 5.5% increase from the previous fiscal year.

Globally, governments and health care organizations are also working to reduce the exorbitant expenses related to cancer treatment. By creating awareness, many health care facilities are also encouraging patients to undergo routine diagnostic tests. For instance, the Centres for Disease Control and Prevention's "Right to Know" campaign is aimed at making women with disabilities aware of the importance of breast cancer screening.

Key Findings:

• The lung cancer cohort had 1,496 patients.
• Stage III and IV malignancies were diagnosed rapidly compared to stage I and II.
• It took about six months for a small number of patients to be diagnosed.
• Information about biopsy was available for 1167 (79.4%) patients with lung cancer: 48.3% were bronchoscopy procedures, 42.8% were guided by CT, and 8.9% underwent surgery.
• The average number of biopsies per patient was 1.25, and 25.7% of patients had multiple biopsies.

Market Drivers

Multidisciplinary Approach Is Required for Lung Cancer Diagnosis

• Directly related to the interdisciplinary approach are many novel ideas brought under this classification: pathologists, surgeons, radiologists, molecular biologists, and clinicians. The primary tenet of this classification is that diagnosing lung cancer is now obviously a multidisciplinary issue. All of the doctors involved in diagnosing lung cancer patients should work closely for making the right diagnosis and getting enough suitable tissue for molecular testing. The reason why each institution must have a multidisciplinary strategy for preserving material for molecular testing is to obtain these small specimens and process them in the pathology laboratory, besides sending specimens to the molecular laboratory for expedited testing and reporting results in a pathology report. It may be helpful to have a multidisciplinary group to actually design this plan and maintain open lines of communication continuously monitoring the concern as it arises. In this approach, pathologists should take a leading role. This should be instituted at the local level because challenges vary greatly between institutions.

Market Opportunities

Increasing Adoption of Minimally Invasive Biopsy Techniques

• This market for biopsy instruments has a huge window of opportunity because of the increasing adoption of minimally invasive biopsy procedures. They are less painful to patients and have periods of recovery and problems associated with their use compared to conventional surgical biopsies. For these reasons, they are both more acceptable to patients and practitioners. The advancements in imaging techniques, including MRI and ultrasound, have improved the accuracy and efficacy of these modalities through their ability to achieve very precise lesion targeting. A growing demand for more sophisticated biopsy technology will be driven by health care systems increasingly demanding patient-centred, cost-effective approaches to care that speed the adoption of less-invasive treatments.

Market Restraining Factors

Risk of infections

• Biopsy techniques can be used to check anomalies at a particular site by radiologists and surgeons. Since these procedures require cuts and incisions to obtain tissue samples, patients are at risk of infections during the process. According to a 2014 publication in The Journal of Urology (Official Journal of the American Urology Association), severe post-prostate biopsy infections are on the rise in Sweden. It was noted that 1% of patients was hospitalized and that the rate of UTIs was approximately 2%, which increased to 6% following 30 days of biopsy. The high risk of infections post-biopsy procedures may restrain the growth of the market.

Segmentation Analysis

The market scope is segmented because of by Product, by Guidance Technique, by Application.

• By Product

Based on the Product of the market is segmented into Needle Based Biopsy Instruments, Liquid Biopsy Instruments, Localization Wire, Biopsy Forceps, Procedure Tray, Biopsy Table, Other Biopsy Products.

Needle-based biopsy guns, which stood at a highest market share of 42.9% led the market, held the biggest market share of the whole industry in 2023, fuelled by a burgeoning demand for biopsy guns from these medical professionals as people request biopsy samples to test from their inner organ's soft tissues. The rising demand for the fast, painless withdrawal of cell specimens for biopsy led to the technology-based development of biopsy devices and tools, of which vacuum-assisted biopsy or VAB tools are one variant. Therefore, in August 2022, Mammotome released its Vacuum-Assisted Breast Biopsy System to support lesion excision. This shall contribute to rapid growth in the market.

The segment of the biopsy needle is likely to increase during the projection period. This is mainly because of the part that is in expansion due to technological advancements and increased need for reaching challenging anatomy during biopsies. The release of advanced products and further innovation will also boost the expansion of the segment. For instance, Cook launched the EchoTip AcuCore EUS biopsy needle in May 2024 for accurate biopsies of gastrointestinal lesions.

• By Guidance Technique

Based on the Guidance Technique of the market is segmented into Image Guided Biopsy, Non-Image Guided Biopsy.

The image-guided biopsy segment has been leading the market for biopsy instruments because of its superior performance and accuracy in the determination of complicated medical diseases. The use of advanced imaging technologies, including ultrasound, computed tomography, magnetic resonance imaging, and mammography, is made for the sensitive targeting of lesions during the biopsy process. The combination of imaging with biopsy tools reduces the chance of sampling errors, lowers the risk of consequences, and increases the doctor's confidence in their diagnosis. Therefore, the method recommended for this purpose is image-guided biopsy, particularly in the case of identifying and diagnosing malignancies in vital organs such as the breasts, liver, and lungs.

This is one of the main reasons why this segment holds the highest level of influence currently, as chronic and lifestyle disorders, such as cancer, often require early and precise detection to be treated effectively. Image-guided modalities can detect a small or deep-seated tumor that cannot be easily identified using non-image-guided treatments. The demand for image-guided biopsies has also increased along with the momentum of minimally invasive treatments; these ensure greater patient comfort and faster recovery times.

Technological advancement in the field of real-time imaging, automation, and AI-based guidance systems is making the image-guided biopsy instruments more accurate and user-friendly. Increased investments in healthcare infrastructure and increased knowledge of early illness diagnosis are also driving the industry.

• Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. The market for biopsy instruments has been dominated by North America because of its sophisticated health care system, high health care costs, and general awareness regarding early disease diagnosis. Its leadership has been further strengthened by the region's steady technical improvements and the presence of important market participants. The need for biopsy operations has been driven by the increased frequency of chronic diseases, including cancer, and a proactive approach to preventative healthcare. The advent of minimally invasive diagnostic methods and government and commercial initiatives supporting cancer screening programs have also made a substantial contribution to market domination. The availability of qualified specialists and favourable reimbursement policies for biopsy treatments has also helped the widespread use of biopsy devices in the region.

However, growth in the Asia-Pacific region would be the most rapid due to its rapidly developed healthcare infrastructure and increasing prevalence of cancer, while awareness about diagnosis at an initial stage is constantly growing. As a result, economic growth experienced by countries, such as China, India, and Japan have resulted in expanding healthcare spending with improved access towards advanced diagnostic instrumentation. Besides, the increased medical tourism industry in this region has attracted people from all walks of life around the world to avail high-quality, reasonably priced medical procedures. Being one of the prime growth engines for the biopsy instruments market, Asia-Pacific is expected to witness growth in the market at a strong pace due to strategies implemented to enhance awareness about cancer and screening as well as innovative technologies.

List of Companies Profiled

• Cardinal Health Inc.
• Hologic, Inc.
• Danaher Corporation
• CONMED Corporation
• Cook Medical
• DTR Medical
• INRAD, Inc.
• Devicor Medical Products Inc.
• Gallini Srl
• TransMed7, LLC.

Key Industry Developments

In April 2024, The FDA has cleared Single Pass's class II medical device, the Kronos biopsy closure device.

In May 2023, In the United States, Argon Medical Devices released its SuperCore Advantage semi-automatic biopsy tool-a soft tissue biopsy product.

In February 2023, TransMed7 announced it would start its US-guided biopsy equipment.

Report Coverage

The report will cover the qualitative and quantitative data on the global Biopsy Devices Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations:

Global Biopsy Devices Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Biopsy Devices market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Biopsy Devices. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Biopsy Devices companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Biopsy Devices Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Biopsy Devices Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Biopsy Devices Market valued?
• Which region has the largest share in 2024 for the global Biopsy Devices Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Biopsy Devices Market

• Historic year: 2019- 2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Billion

Biopsy Devices Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: